Everlab’s AU$65m Series A raises the stakes for preventive health platforms
Find out how Everlab’s AU$65m Series A could reshape AI preventive healthcare, diagnostics, patient data and scalable care access.
Medical Devices & Diagnostics
Pharma & Biotech
Could DermaSensor’s NHS study turn AI skin cancer tools into primary care infrastructure?
Find out how DermaSensor’s CE Mark and NHS study could reshape AI-assisted skin cancer assessment across European primary care.
Medical Devices & Diagnostics
Geneoscopy’s ColoSense Medicare win puts stool RNA testing into the colorectal screening mainstream
Medicare coverage gives ColoSense a bigger test: can stool RNA screening move from FDA approval to real colorectal cancer adoption?
Medical Devices & Diagnostics
Why the Radoff-JEC bid for Seer is bigger than a small-cap biotech takeover fight
Find out why Seer’s activist battle could reshape investor thinking on proteomics, diagnostics platforms and biotech value creation.
Medical Devices & Diagnostics
GHO Capital and CBC Group deal signals a bigger private capital push into life sciences
GHO Capital and CBC Group are creating a $21bn healthcare investor. Find out what it means for pharma, medtech and life sciences funding.
Medical Devices & Diagnostics
Can Europe contain its STI surge before antimicrobial resistance narrows treatment options?
Europe’s STI surge is testing diagnostics, prevention and treatment capacity as gonorrhoea and syphilis reach record levels.
Medical Devices & Diagnostics
SOLVD Health broadens AvertD access as FDA clears blood-based sample collection
FDA cleared blood-based collection for SOLVD Health’s AvertD. Find out why this could expand genetic opioid risk testing in surgical care.
Medical Devices & Diagnostics
Is Legacy’s vasectomy solution setting a new standard for post-procedure patient management?
Legacy’s new AUA-aligned vasectomy platform combines sperm banking and mail-in PVSA—find out how it could reshape male fertility care in the U.S.
Medical Devices & Diagnostics
FDA clears VizMark’s VM1 tumor marker: Is this the fix for MRI artifact in breast imaging?
VizMark’s VM1 marker receives FDA clearance for artifact-free breast imaging. Find out how this may change tumor localization in dense breast cases.
Pharma & Biotech
Can Bio-Techne and Wyss Geneva make 3D spatial biology mainstream?
Bio-Techne Corporation has announced a strategic partnership with the Wyss Center for Bio and Neuroengineering in Geneva to develop an automated platform for simultaneous RNA and protein detection in 3D tissue samples. The collaboration aims to reduce technical complexity and accelerate adoption of spatial biology tools by enabling high-resolution multiomic analysis in intact three-dimensional specimens.